Takeda recalled of NATPARA (a parathyroid hormone) in US
Takeda Pharmaceutical Company Limited, on 6 Sep 2019, announced that the company is issuing a US recall for all doses of NATPARA®... Read More
Takeda, Frazier Healthcare Partners to launch Phathom Pharma
Takeda Pharmaceutical and Frazier Healthcare Partners have announced a collaboration to launch Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and... Read More
Novatis’s Xiidra acquisition from Takeda for USD 5.3 billion
Novartis has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets associated with Xiidra (lifitegrast ophthalmic solution) 5%... Read More
Takeda subsidiary Millennium Pharmaceuticals Inc, sues Aurobindo to block generic Velcade
A U.S. unit of Japan’s Takeda Pharmaceutical Co has sued generic drugmaker Aurobindo Pharma Ltd over its plans to make a cheaper... Read More
Consequences and progress of Takeda-Shire Buyout
Takeda announced in April it would buy Shire in the largest-ever overseas acquisition by a Japanese company. Although Shire is based in... Read More
Big Pharma Acquisition: Takeda to acquire Shire for $62 billion
Takeda Pharmaceutical Co. of Japan has finalized an agreement to buy Shire PLC, the second-biggest biotech employer in Massachusetts, for $62 billion... Read More
Samsung Bioepis and Takeda’s Co-development deal for novel biologics
Korean biosimilars manufacturer Samsung Bioepis Co Ltd. will team up with Japanese drugmaker Takeda Pharmaceutical Company to jointly develop new biologic therapies.... Read More
Infinity Amends PI3K-Delta,Gamma Agreement with Takeda Oncology
Infinity Pharmaceuticals, Inc., an innovative biopharmaceutical company, has amended its license agreement with Takeda Oncology for IPI-549, Infinity’s potentially first-in-class immuno-oncology product... Read More
Takeda – Finch Therapeutics drug development & commercialization deal for IBD molecule
Takeda is paying Finch Therapeutics $10 million upfront for exclusive, global rights to develop and commercialize the latter’s inflammatory bowel disease (IBD)... Read More
TAKEDA to Acquire ARIAD Pharmaceuticals to stregthen oncology portfolio
Posted on11 Jan 2017
Comments0
Acquiring Company: Takeda Pharmaceutical Company Limited Acquired Company: ARIAD Pharmaceuticals, Inc Overall Deal Value: approximately $5.2 billion Why this deal? Highly strategic deal which transforms... Read More